Battelle, CMC Pharmaceuticals Secure $53M DOD Contract for Nerve Agent Countermeasure Development
Battelle, a global research and development company, and subcontractor CMC Pharmaceuticals have been awarded a 6.5-year, $53 million contract by the Department of Defense to develop a nerve agent countermeasure.
The deal aims to ensure that U.S. military personnel have a stronger chance of surviving and recovering from nerve agent exposure, Battelle said Monday.
Under the contract, Battelle and CMC will work together to develop the Reactivating Nerve Agent Treatment System. The RNATS is a reactivator in a vial designed to combat the effects of nerve agents and similar chemical weapons.
Read the full article here.